Healio Gastroenterology Current Issue
The following articles appeared in the print edition of Healio Gastroenterology.
Table of Contents
- ‘Unequivocally yes’: MASH therapies still needed despite boom in GLP-1 use in liver disease Monica Stonehill
-
- Manage lifestyle early and aggressively to prevent, instead of treat, fatty liver Rita Basu, MD
- ‘Future of treating MASH’ will combine GLP-1 drugs, liver-specific medications Scott Isaacs, MD, FACP, FACE
- More data needed on GLP-1s, dual agonists to reach ‘optimal’ management of MASH, diabetes Rohit Loomba, MD, MHSc
- ‘Whether or not we like it,’ GLP-1s are part of hepatology, treatment of MASH Arun Sanyal, MD
- ‘Highly plausible’ GLP-1s can improve health-related QoL, economic burden of MASH Zobair M. Younossi, MD, MPH
- AGA recommends endoscopic eradication vs. surveillance for BE with high-grade dysplasia Kate Burba
- AMA: Drug, device sponsors need to include women, LGBTQ+ patients in trials Stephanie C. Viguers
- CRC incidence more than triples among children, teens from 1999 to 2020 Kate Burba
-
- DAA treatment ‘longitudinally continues to improve’ liver-related survival in HCV Kate Burba
- Endoscopic ablation reduces primary hunger hormone by up to 53% in obesity Kate Burba
- FDA approves Ipsen’s Iqirvo ‘to address unmet need’ in primary biliary cholangitis
- FDA panel backs Guardant’s colorectal cancer blood test for favorable risk-benefit
- FDA rejects expanded use of Dynavax’s four-dose hepatitis B vaccine for hemodialysis
- Larsucosterol rebounds to snag FDA breakthrough status for alcohol-related hepatitis
- Q&A: ‘Future is bright’ for use of microbiota therapeutics in patients with IBD Kate Burba; Ari Grinspan, MD
- Rifaximin ‘cannot be recommended’ as antibiotic prophylaxis for severe cirrhosis, ascites Monica Stonehill
-
- Statin use linked to ‘sharp 86% risk reduction’ for primary sclerosing cholangitis in IBD Kate Burba
- Survodutide improves MASH without worsening of fibrosis in more than 64% at 48 weeks Kate Burba
- ‘Unprecedented level of fibrosis improvement’ through 96 weeks with efruxifermin for MASH Monica Stonehill
- VIDEO: Bulevirtide plus PEG-IFN a-2a potentially ‘viable finite therapy’ for chronic HDV Anu Osinusi, MD, MPH; Kate Burba
- VIDEO: Lifetime disruptor ‘just getting started’ in quest to elevate care for IBD patients Monica Stonehill; Marla C. Dubinsky, MD
- Weight gain during diet therapy linked to ‘worse EoE outcomes’ no matter baseline weight Robert Stott